A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy

• Published in: Molecular medicine reports Vol. 25; no. 3
• Main Authors: Nonaka, Wakako, Takata, Tadayuki, Iwama, Hisakazu, Komatsubara, Satoshi, Kobara, Hideki, Kamada, Masaki, Deguchi, Kazushi, Touge, Tetsuo, Miyamoto, Osamu, Nakamura, Takehiro, Itano, Toshifumi, Masaki, Tsutomu
• Format: Journal Article
• Language: English
• Published: Greece Spandidos Publications 01-03-2022; Spandidos Publications UK Ltd; D.A. Spandidos
• Subjects: Age; Aged; Aged, 80 and over; Alzheimer's disease; Autophagy; Bioinformatics; Biomarkers; Biomarkers - cerebrospinal fluid; Cerebrospinal fluid; Chromosome 5; Dementia disorders; Development and progression; Diagnosis; Epigenetics; Etiology; Female; Gene expression; Gene Expression Profiling - methods; Gene Expression Regulation; Genetic aspects; Health aspects; Humans; Male; Medical imaging; Mental disorders; MicroRNA; MicroRNAs; MicroRNAs - cerebrospinal fluid; MicroRNAs - genetics; Middle Aged; miRNA; Neurodegenerative diseases; Neuroimaging; Paralysis; Parkinson's disease; Pathogenesis; Patients; Progressive supranuclear palsy; Proteasomes; Puncture; Sensitivity and Specificity; Spine; Statistical analysis; Supranuclear Palsy, Progressive - cerebrospinal fluid; Supranuclear Palsy, Progressive - diagnosis; Supranuclear Palsy, Progressive - genetics; Syndrome; Tau protein; Ubiquitin; Japan; microRNA; humans; Parkinson's and related diseases; cerebrospinal fluid; progressive supranuclear palsy
• ISSN: 1791-2997; 1791-3004
• DOI: 10.3892/mmr.2022.12604

Progressive supranuclear palsy (PSP) is a neurodegenerative tauopathy described as a syndrome of postural instability, supranuclear vertical gaze palsy, dysarthria, dystonic rigidity of the neck and trunk, dementia, and pseudobulbar palsy. The clinical diagnosis of PSP is often difficult because there are no established biomarkers, and diagnosis is currently based on clinical and imaging findings. Furthermore, the etiology and pathogenesis of PSP remain unknown. Dysregulation of microRNAs (miRNAs/miRs) has been reported to serve an important role in neurodegenerative diseases. However, the miRNA profiles of patients with PSP are rarely reported. The present study aimed to examine cerebrospinal fluid miRNAs, which are considered to be more sensitive indicators of changes in the brain, to elucidate the pathophysiology of PSP and to establish specific biomarkers for diagnosis. The present study used a microarray chip containing 2,632 miRNAs to examine cerebrospinal fluid miRNA expression levels in 11 patients with PSP aged 68‑82 years. A total of 8 age‑ and sex‑matched controls were also included. A total of 38 miRNAs were significantly upregulated and one miRNA was significantly downregulated in the cerebrospinal fluid of patients with PSP. The patients were divided into two groups based on disease stage (early onset and advanced), and changes in miRNA expression were examined. The miRNAs that were most significantly upregulated or downregulated in the early onset group were miR‑204‑3p, miR‑873‑3p and miR‑6840‑5p. The target genes of these miRNAs were associated with molecules related to the ubiquitin‑proteasome system and autophagy pathway. Furthermore, these miRNAs were found to target genes that have been reported to have epigenetic changes following an epigenome‑wide association study of brain tissues of patients with PSP. This suggested that these miRNAs and genes may have some involvement in the pathogenesis of PSP. However, the sample size of the present study was small; therefore, a greater number of patients with PSP should be examined in future studies.